Evexia Lifecare (EVEXIA) Q2 FY27 Profit Slumps 38% as Revenue Declines for Second Straight Quarter
The chemical trader's earnings fell sharply year-on-year and quarter-on-quarter, with auditors flagging significant credit risk in its receivables.
Evexia Lifecare's Q2 FY27 saw revenue fall 2.8% YoY and profit drop 37.8%. The statutory auditor issued a disclaimer, citing an inability to assess credit risk on substantial receivables.
For Evexia Lifecare, a chemicals and commodities trader, the second quarter extended a slide from a brief peak. Revenue and profit both declined from the previous year and the prior quarter, underscoring a business struggling for momentum amid broader industry pressures and internal financial questions.
The numbers show a clear downtrend. Revenue of ₹25.02 crore was down 2.8% from a year ago and fell 19% from the June quarter. Profit fell even harder, dropping 37.8% year-on-year to ₹0.23 crore. The net profit margin compressed to 0.9%, down 50 basis points from Q2 FY26.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Period | Sep 2026 | Jun 2026 | Sep 2025 |
| Revenue (₹ Cr) | 25.02YoY -2.8% | 30.89 | 25.73 |
| Profit (₹ Cr) | 0.23YoY -38% | 0.41 | 0.37 |
| Net Profit Margin (%) | 0.9YoY -36% | 1.3 | 1.4 |
The auditor's disclaimer overshadows the numbers
The financials arrived with a significant qualification. Statutory auditor Tejas K. Soni & Company issued a disclaimer of conclusion on the standalone results. As reported by ScanX, the auditor highlighted loans and trade receivables totalling ₹36.79 crore that showed a significant increase in credit risk.
The company did not make an expected credit loss assessment, as management considered the balances recoverable. This gap means the reported profit of ₹0.23 crore may not reflect potential future impairment losses.
A stagnant business in a tough market
Research from StockFin.ai suggests the company is in a phase of financial stagnation with no new orders or strategic initiatives disclosed. The chemical trading industry itself faces headwinds. A Crisil Ratings analysis cited by PolymerUpdate notes subdued exports and pricing pressure from Chinese competitors are compressing margins for Indian specialty chemical firms.
For a trader like Evexia, these conditions limit both volume growth and pricing power. The lack of a visible order book or management commentary on future performance, as noted in the research, offers little near-term optimism.
Cash is draining while debt has ballooned
The consolidated cash flow statement for the half-year ended September 2026 showed a net decrease in cash of ₹1.08 crore. Meanwhile, the balance sheet has seen a dramatic rise in borrowings. According to StockFin.ai, debt surged to ₹1,222 crore as of March 2026 from ₹386 crore a year earlier, while equity remained flat.
This aggressive leverage, without corresponding profit growth, raises clear solvency concerns. The company's debt-to-equity ratio stands at 0.87.
Key Points
- Revenue declined 2.8% year-on-year and 19% quarter-on-quarter to ₹25.02 crore in Q2 FY27.
- Profit fell more sharply, down 37.8% YoY to ₹0.23 crore, with net margin compressing to 0.9%.
- Statutory auditors disclaimed an opinion, flagging ₹36.79 crore in receivables with heightened credit risk and no expected loss provision.
- The business shows no signs of strategic revival, with research indicating stagnant operations and no forward guidance.
- Debt has risen sharply against flat equity, raising financial risk amid weak cash generation.
Hexa Perspective
The quarter's story is one of operational decline compounded by accounting uncertainty. The auditor's disclaimer on receivables casts a long shadow, suggesting reported profits are fragile. With revenue retreating from its March peak and the chemical trading environment challenging, a turnaround appears distant. Investors are left weighing a business with minimal scale, rising leverage, and now, questions over the quality of its assets. The path forward requires not just a demand recovery but a credible plan to address the balance sheet and restore confidence in its financial reporting.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.